Functional alterations of myeloid cell subsets in hyperlipidaemia: Relevance for atherosclerosis

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4293-4303

  Soehnlein, Oliver ^a   Drechsler, Maik ^a   Hristov, Mihail ^a   Weber, Christian ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Dendritic cell; Endothelial progenitor cell; Hyperlipidaemia; Monocyte; Neutrophil

Indexed keywords

ANIMAL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; HUMAN; HYPERLIPIDEMIA; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; MYELOID CELLS; RISK FACTORS;

EID: 77951292613     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00965.x     Document Type: Article

References (135)

1. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009, 6:399-409.
2. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008, 8:802-15.
3. Soehnlein O, Weber C. Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol. 2009, 31:35-47.
4. Mause SF, Weber C. Intrusion through the fragile back door immature plaque microvessels as entry portals for leukocytes and erythrocytes in atherosclerosis. J Am Coll Cardiol. 2009, 53:1528-31.
5. Rotzius P, Soehnlein O, Kenne E. ApoE(-/-)/lysozyme M(EGFP/EGFP) mice as a versatile model to study monocyte and neutrophil trafficking in atherosclerosis. Atherosclerosis. 2009, 202:111-8.
6. Zernecke A, Bot I, Djalali-Talab Y. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008, 102:209-17.
7. Yvan-Charvet L, Welch C, Pagler TA. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008, 118:1837-47.
8. Thomas HE, Kannel WB, Dawber TR. Cholesterol-phospholipid ratio in the prediction of coronary heart disease. The Framingham study. N Engl J Med. 1966, 274:701-5.
9. Houterman S, Verschuren WM, Hofman A. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med. 1999, 246:25-33.
10. Mills GL, Taylaur CE. The distribution and composition of serum lipoproteins in eighteen animals. Comp Biochem Physiol B. 1971, 40:489-501.
11. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol. 2009, 31:127-42.
12. Ylitalo R, Oksala O, Ylä-Herttuala S. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med. 1994, 123:769-76.
13. Stoneman V, Braganza D, Figg N. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res. 2007, 100:884-93.
14. Napoli C, D'Armiento FP, Mancini FP. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997, 100:2680-90.
15. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol. 2001, 69:11-20.
16. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8:958-69.
17. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2006, 5:953-64.
18. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003, 19:71-82.
19. Weber C, Belge KU, von Hundelshausen P. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol. 2000, 67:699-704.
20. Tacke F, Alvarez D, Kaplan TJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007, 117:185-94.
21. Braunersreuther V, Zernecke A, Arnaud C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007, 27:373-9.
22. Combadière C, Potteaux S, Rodero M. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008, 117:1649-57.
23. Boring L, Gosling J, Cleary M. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998, 394:894-7.
24. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001, 173:35-43.
25. Ley K, Laudanna C, Cybulsky MI. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007, 7:678-89.
26. An G, Wang H, Tang R. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation. 2008, 117:3227-37.
27. Auffray C, Fogg D, Garfa M. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007, 317:666-70.
28. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006, 26:1702-11.
29. Babaev VR, Gleaves LA, Carter KJ. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2000, 20:2593-9.
30. Manning-Tobin JJ, Moore KJ, Seimon TA. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2009, 29:19-26.
31. Draude G, von Hundelshausen P, Frankenberger M. Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. Am J Physiol. 1999, 276:H1144-9.
32. Barron HV, Cannon CP, Murphy SA. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000, 102:2329-34.
33. Cannon CP, McCabe CH, Wilcox RG. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001, 87:636-9.
34. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 1974, 290:1275-8.
35. Afiune Neto A, Mansur Ade P, Avakian SD. [Monocytosis is an independent risk marker for coronary artery disease]. Arq Bras Cardiol. 2006, 86:240-4.
36. Tani S, Nagao K, Anazawa T. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol. 2009, 104:464-9.
37. Feldman DL, Mogelesky TC, Liptak BF. Leukocytosis in rabbits with diet-induced atherosclerosis. Arterioscler Thromb. 1991, 11:985-94.
38. Averill LE, Meagher RC, Gerrity RG. Enhanced monocyte progenitor cell proliferation in bone marrow of hyperlipemic swine. Am J Pathol. 1989, 135:369-77.
39. Swirski FK, Libby P, Aikawa E. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007, 117:195-205.
40. Wu H, Gower RM, Wang H. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009, 119:2708-17.
41. Benítez MB, Cuniberti L, Fornari MC. Endothelial and leukocyte adhesion molecules in primary hypertriglyceridemia. Atherosclerosis. 2008, 197:679-87.
42. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol. 1998, 18:1983-91.
43. Han KH, Han KO, Green SR. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res. 1999, 40:1053-63.
44. Han KH, Ryu J, Hong KH. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005, 111:1439-47.
45. Veillard NR, Braunersreuther V, Arnaud C. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006, 188:51-8.
46. Quinn MT, Parthasarathy S, Fong LG. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA. 1987, 84:2995-8.
47. Sakai M, Miyazaki A, Hakamata H. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1996, 16:600-5.
48. Fuhrman B, Koren L, Volkova N. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis. 2002, 164:179-85.
49. Fuhrman B, Partoush A, Volkova N. Ox-LDL induces monocyte-to-macrophage differentiation in vivo: possible role for the macrophage colony stimulating factor receptor (M-CSF-R). Atherosclerosis. 2008, 196:598-607.
50. Feng J, Han J, Pearce SF. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res. 2000, 41:688-96.
51. Nagy L, Tontonoz P, Alvarez JG. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998, 93:229-40.
52. Han KH, Chang MK, Boullier A. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest. 2000, 106:793-802.
53. Barlic J, Zhang Y, Foley JF. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation. 2006, 114:807-19.
54. Trillo AA. The cell population of aortic fatty streaks in African green monkeys with special reference to granulocytic cells. An ultrastructural study. Atherosclerosis. 1982, 43:259-75.
55. Kathiresan S, Voight BF. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009, 41:334-41. Myocardial Infarction Genetics Consortium
56. Kawaguchi H, Mori T, Kawano T. Band neutrophil count and the presence and severity of coronary atherosclerosis. Am Heart J. 1996, 132:9-12.
57. Sweetnam PM, Thomas HF, Yarnell JW. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol. 1997, 145:416-21.
58. Soehnlein O. An elegant defense: how neutrophils shape the immune response. Trends Immunol. 2009, 30:511-2.
59. DiStasi MR, Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 2009, 30:547-56.
60. Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009, 30:538-46.
61. Yang D, de la Rosa G, Tewary P. Alarmins link neutrophils and dendritic cells. Trends Immunol. 2009, 30:531-7.
62. Muller I, Munder M, Kropf P. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms. Trends Immunol. 2009, 30:522-30.
63. Edfeldt K, Agerberth B, Rottenberg ME. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2006, 26:1551-7.
64. Barnathan ES, Raghunath PN, Tomaszewski JE. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol. 1997, 150:1009-20.
65. Lee TD, Gonzalez ML, Kumar P. CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions. Am J Pathol. 2002, 160:841-8.
66. Soehnlein O, Xie X, Ulbrich H. Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. J Immunol. 2005, 174:6399-405.
67. Gautam N, Olofsson AM, Herwald H. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 2001, 7:1123-7.
68. Di Gennaro A, Kenne E, Wan M. Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB J. 2009, 23:1750-7.
69. Soehnlein O, Oehmcke S, Ma X. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur Respir J. 2008, 32:405-12.
70. Soehnlein O, Zernecke A, Eriksson EE. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008, 112:1461-71.
71. Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood. 2009, 114:4613-23.
72. Soehnlein O, Kai-Larsen Y, Frithiof R. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest. 2008, 118:3491-502.
73. Luttun A, Lutgens E, Manderveld A. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004, 109:1408-14.
74. Eliason JL, Hannawa KK, Ailawadi G. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005, 112:232-40.
75. Pagano MB, Bartoli MA, Ennis TL. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci USA. 2007, 104:2855-60.
76. Brennan ML, Anderson MM, Shih DM. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest. 2001, 107:419-30.
77. Kirk EA, Dinauer MC, Rosen H. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000, 20:1529-35.
78. Araujo FB, Barbosa DS, Hsin CY. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis. 1995, 117:61-71.
79. Mazor R, Shurtz-Swirski R, Farah R. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis. 2008, 197:937-43.
80. Fontana L, Giagulli C, Cominacini L. Beta2 integrin-dependent neutrophil adhesion induced by minimally modified low-density lipoproteins is mainly mediated by F2-isoprostanes. Circulation. 2002, 106:2434-41.
81. Lehr HA, Krombach F, Münzing S. In vitro effects of oxidized low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo situation. Am J Pathol. 1995, 146:218-27.
82. Sedgwick JB, Hwang YS, Gerbyshak HA. Oxidized low-density lipoprotein activates migration and degranulation of human granulocytes. Am J Respir Cell Mol Biol. 2003, 29:702-9.
83. van Tits LJ, Hak-Lemmers HL, Demacker PN. Oxidized low-density lipoprotein induces calcium influx in polymorphonuclear leukocytes. Free Radic Biol Med. 2000, 29:747-55.
84. Maher BM, Dhonnchu TN, Burke JP. Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects. J Leukoc Biol. 2009, 85:186-93.
85. Dje N'Guessan P, Riediger F, Vardarova K. Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 2009, 29:380-6.
86. Zineh I, Beitelshees AL, Welder GJ. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS One. 2008, 3:e3117.
87. Nakamura K, Sasaki T, Cheng XW. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis. 2009, 206:351-2.
88. Agis H, Willheim M, Sperr WR. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol. 1993, 151:4221-7.
89. Födinger M, Fritsch G, Winkler K. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994, 84:2954-9.
90. Kirshenbaum AS, Goff JP, Semere T. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999, 94:2333-42.
91. CONSTANTINIDES P. Mast cells and susceptibility to experimental atherosclerosis. Science. 1953, 117:505-6.
92. Kovanen PT. Mast cells and degradation of pericellular and extracellular matrices: potential contributions to erosion, rupture and intraplaque haemorrhage of atherosclerotic plaques. Biochem Soc Trans. 2007, 35:857-61.
93. Bot I, de Jager SC, Zernecke A. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007, 115:2516-25.
94. Sun J, Sukhova GK, Wolters PJ. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007, 13:719-24.
95. Sun J, Sukhova GK, Yang M. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007, 117:3359-68.
96. Kelley J, Hemontolor G, Younis W. Mast cell activation by lipoproteins. Methods Mol Biol. 2006, 315:341-8.
97. Lindstedt KA, Mäyränpä MI, Kovanen PT. Mast cells in vulnerable atherosclerotic plaques-a view to a kill. J Cell Mol Med. 2007, 11:739-58.
98. Kovanen PT. Mast cells in atherogenesis: actions and reactions. Curr Atheroscler Rep. 2009, 11:214-9.
99. Millonig G, Niederegger H, Rabl W. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol. 2001, 21:503-8.
100. Liu P, Yu YR, Spencer JA. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol. 2008, 28:243-50.
101. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J. 2005, 26:1700-4.
102. Yilmaz A, Lochno M, Traeg F. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis. 2004, 176:101-10.
103. Niessner A, Sato K, Chaikof EL. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation. 2006, 114:2482-9.
104. Zaguri R, Verbovetski I, Atallah M. 'Danger' effect of low-density lipoprotein (LDL) and oxidized LDL on human immature dendritic cells. Clin Exp Immunol. 2007, 149:543-52.
105. Angeli V, Llodrá J, Rong JX. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity. 2004, 21:561-74.
106. Shamshiev AT, Ampenberger F, Ernst B. Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med. 2007, 204:441-52.
107. Packard RR, Maganto-García E, Gotsman I. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res. 2008, 103:965-73.
108. Yilmaz A, Reiss C, Tantawi O. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004, 172:85-93.
109. Kofler S, Schlichting C, Jankl S. Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. Atherosclerosis. 2008, 197:105-10.
110. Yilmaz A, Reiss C, Weng A. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006, 79:529-38.
111. Hristov M, Zernecke A, Liehn EA. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost. 2007, 98:274-7.
112. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2008, 8:498-508.
113. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008, 28:1584-95.
114. Timmermans F, Van Hauwermeiren F, De Smedt M. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007, 27:1572-9.
115. Bertolini F, Shaked Y, Mancuso P. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer. 2006, 6:835-45.
116. Gehling UM, Ergün S, Schumacher U. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000, 95:3106-12.
117. Peichev M, Naiyer AJ, Pereira D. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000, 95:952-8.
118. Case J, Mead LE, Bessler WK. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007, 35:1109-18.
119. Romagnani P, Annunziato F, Liotta F. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res. 2005, 97:314-22.
120. Elsheikh E, Uzunel M, He Z. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood. 2005, 106:2347-55.
121. Hristov M, Zernecke A, Bidzhekov K. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007, 100:590-7.
122. Murdoch C, Tazzyman S, Webster S. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. 2007, 178:7405-11.
123. De Palma M, Murdoch C, Venneri MA. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007, 28:519-24.
124. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med. 2003, 13:201-6.
125. Rehman J, Li J, Orschell CM. Peripheral blood " endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003, 107:1164-9.
126. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy. Arterioscler Thromb Vasc Biol. 2006, 26:257-66.
127. Hill JM, Zalos G, Halcox JP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348:593-600.
128. Schmidt-Lucke C, Rössig L, Fichtlscherer S. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005, 111:2981-7.
129. Tepper OM, Galiano RD, Capla JM. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002, 106:2781-6.
130. Müller-Ehmsen J, Braun D, Schneider T. Decreased number of circulating progenitor cells in obesity: beneficial effects of weight reduction. Eur Heart J. 2008, 29:1560-8.
131. Pirro M, Bagaglia F, Paoletti L. Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis. 2008, 2:329-39.
132. Cheng J, Cui R, Chen CH. Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology. 2007, 148:2085-94.
133. Noor R, Shuaib U, Wang CX. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis. 2007, 192:92-9.
134. Tso C, Martinic G, Fan WH. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006, 26:1144-9.
135. George J, Afek A, Abashidze A. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2005, 25:2636-41.